CD274 and neoplasm: To help differentiate a cell intrinsic role of PD-L1 on cell metabolism in absence of ligand from a ligand induced effect on the tumor cells, 786-O and A498 cell lines were treated with three PD-L1 blocking therapeutic antibodies (avelumab, durvalumab and atezolizumab) and a purified ligand (PD-1-Fc; 0.1 ug/mL) and their metabolic functions were analysed using a seahorse bioanalyzer.